Media Fill Testing in Hospital Aseptic Units: A Guide to EU GMP Annex 1 Alignment

How aseptic process simulation confirms a hospital compounding process is truly sterile.

In this article, you’ll learn: 

• What media fill testing actually demonstrates about a hospital aseptic unit’s process, beyond the pass or fail result 

• How the revised EU GMP Annex 1 has changed expectations for aseptic process simulation design and frequency 

• Where the European Pharmacopoeia and USP frameworks fit alongside Annex 1 in sterility assurance 

• Why hospital aseptic units need different approaches to media fill compared with industrial manufacturers 

• How to build worst-case conditions into a media fill so it tests what actually happens under pressure 

• What a failed media fill test means, and why a pass is not the same as a guarantee of sterility 

Media fill testing provides evidence that a hospital aseptic unit’s compounding process can consistently maintain aseptic conditions. This is achieved by substituting a sterile microbiological growth medium for the real drug product, then carrying out every manipulation, intervention, and duration exactly as they occur in routine operation.

An incubation period with no microbial growth indicates that personnel, equipment, and procedure are effective. Because preparations such as chemotherapy infusions, parenteral nutrition, and ophthalmic products are administered directly to patients, this evidence isn’t a formality: it’s one of the strongest indicators that the aseptic process can consistently protect product quality and patient safety.

Why are ICP instruments sensitive to unfiltered samples? 

In ICP-OES and ICP-MS workflows, filtration is the sample preparation step that removes suspended particulates from a digested sample before that sample reaches the instrument. This protects both the instrument’s components, and analytical accuracy.

The sample introduction system on ICP is designed to transport a liquid sample and generate a stable, fine aerosol. Digested environmental samples such as wastewater, soil extracts, and sediment leachates routinely carry residual particulates the naked eye can’t detect, and suspended solids increase the risk of clogging, unstable aerosol formation, deposition and drift. Consequences of inadequate filtration range from signal instability and elevated backgrounds to physical blockage. Because potential damage builds up gradually, filtration is often treated as a minor step, even though it directly determines whether a result can be trusted.

In many regulated methods for dissolved metals, filtration is a required or method-defining step. This is the case in EPA 6020B, for example, where dissolved constituents must be filtered and acid-preserved before analysis, or EPA 3005A, where dissolved metals are filtered through a 0.45 µm filter at collection before acidification. For other workflows, especially total recoverable or acid-leachable determinations, filtration may occur later, or may not define the reported fraction. But because filtration can alter contamination background and analyte recovery, it should always be method-aligned and validated. In all cases, it’s the point at which months of careful method development either hold or fail.

What is media fill testing in a hospital aseptic unit?

Media fill testing, also known as aseptic process simulation (APS), is a process simulation in which a sterile microbiological growth medium — typically Tryptic Soy Broth (TSB) — replaces the drug product throughout an aseptic compounding procedure. The filled units are then incubated and examined for microbial growth. Absence of growth is evidence that the process is capable of being performed without introducing microbial contamination under the conditions simulated.

This exercise carries a different emphasis in a hospital aseptic unit than in an industrial manufacturing plant. Hospital pharmacies typically produce patient-specific preparations in small batches. This means a media fill is less about validating a large-scale automated line, but more about validating the technique of the individual operator performing the compounding.

A hospital media fill doesn’t answer the question “can this equipment run for a shift without contaminating a batch?”, but “can this person, performing this manipulation, in this environment, do so without introducing a microorganism?” That distinction shapes almost everything else about how hospital media fill programs should be designed.

What does EU GMP Annex 1 require for aseptic process simulation?

The revised EU GMP Annex 1, Manufacture of Sterile Medicinal Products, was published in August 2022, with the majority of its provisions taking effect in August 2023. Annex 1 sets out considerably more detailed and risk-based expectations for aseptic process simulation than the version it replaced, and positions media fills as a central pillar of a facility’s wider Contamination Control Strategy (CCS) — the documented framework that identifies every critical control point in a sterile manufacturing process, and the measures used to manage the risk at each one.

Annex 1 specifies that aseptic process simulations should:

• Simulate the entire aseptic process, including all critical manufacturing steps
• Include both routine and worst-case interventions
• Reflect actual operating conditions rather than idealized ones
• Demonstrate the effectiveness of the CCS
• Be repeated at defined intervals, and following any significant change to the process
• Qualify personnel individually for the aseptic activities they perform

Regarding frequency, Annex 1 stipulates that aseptic process simulations should be performed at least twice annually for each processing line and shift combination, that every operator involved in aseptic activities should participate in at least one successful simulation a year, and that initial validation of a new process requires three consecutive successful runs before it’s considered qualified.

Many hospital aseptic units adopt similar frequencies as a matter of risk-based best practice, although local regulatory frameworks and hospital pharmacy standards may also apply. This is because the underlying logic that confidence in process capability decreases over time, and must periodically be re-established, is just as applicable to a hospital compounding room as to an industrial filling line.

Annex 1 requires culture media used for aseptic process simulation and environmental monitoring to be demonstrated as suitable through growth promotion testing. This may be performed by the manufacturer or end user, provided the suitability and use conditions are appropriately justified.

For hospital pharmacies without extensive in-house microbiology capabilities, ready-to-use, quality-controlled TSB formulations can simplify compliance with growth promotion testing requirements. Solutions such as AnalytiChem’s Redipor® range are supplied with certificates of analysis documenting completed quality control testing.

How do the European Pharmacopoeia and USP frameworks reinforce Annex 1?

Sterility assurance under both the European Pharmacopoeia (Ph. Eur.) and the United States Pharmacopeia (USP) rests on validated process control rather than on end-product testing alone. This is why the process simulation itself, and not a final sterility test, carries the evidential weight in a media fill program.

Ph. Eur. General Chapter 2.6.1, Sterility, describes the microbiological methods used to detect contamination in a finished batch, and it is harmonized with USP General Chapter 71, Sterility Tests. In isolation, neither chapter can prove that an entire batch is sterile: sterility testing samples only a small fraction of any batch, so while a negative result reduces uncertainty, it doesn’t eliminate it completely. This is the gap process validation is designed to close.

USP General Chapter <797>, Pharmaceutical Compounding – Sterile Preparations, frames media fill testing as a direct evaluation of an individual operator’s aseptic technique, distinct from testing the finished preparation itself. Together, these three frameworks describe a layered system:

• Environmental monitoring and personnel qualification build confidence in the process as it runs
• Media fill testing demonstrates the process is capable of producing sterile output under realistic conditions
• End-product sterility testing provides a final, necessarily limited, check

Hospital aseptic units should not treat media fill testing as interchangeable with sterility testing.

Why do hospital aseptic units need a different approach to media fill design?

Hospital aseptic units face a materially different risk profile from industrial pharmaceutical manufacturers. A media fill protocol copied wholesale from an industrial context will miss the risks that matter in a hospital setting. While an industrial line produces the same product repeatedly through largely automated equipment, a hospital pharmacy compounds a wide variety of patient-specific formulations, often in small batches, using a correspondingly wide variety of syringes, infusion bags, elastomeric devices, and other delivery systems, each of which has its own connection points and manipulation sequence. For example, a chemotherapy preparation requiring multiple vial entries, syringe transfers and infusion bag manipulations represents a more challenging aseptic process than a simple single-transfer preparation. A media fill designed around these higher-risk activities provides a more meaningful assessment of operator technique and process robustness.

A media fill protocol designed for this environment should reflect:

• The most complex compounding procedures the unit actually performs, not a simplified representative example
• The highest-risk manipulations, such as multiple transfers, reconstitutions, or pooling steps
• The different container and delivery formats in routine use
• Peak workload conditions, when time pressure is greatest
• The interruptions and interventions that occur in normal practice, not an uninterrupted best case

Designing to this level of specificity takes more effort than running a generic simulation, but is also what makes the result meaningful. A media fill test that omits the unit’s most demanding procedure hasn’t tested the unit’s greatest risk, whatever the pass rate indicates.

What are the most common sources of contamination during aseptic compounding?

Most contamination introduced during aseptic compounding originates with human intervention rather than with equipment or facility failure, which is precisely why personnel technique is the primary factor a hospital media fill is designed to test. Several behaviors recur most often as contamination risks:

• Incorrect gowning technique
• Poor hand and surface disinfection practice
• Excessive or unnecessary movement within the cleanroom
• Improper transfer of materials into the critical processing zone
• Inadequate cleaning or environmental control
• Deviation from standard operating procedures, even where the deviation seems minor

None of these behaviors is unusual or difficult to imagine — and that’s the point. Media fill testing exists to identify small, everyday lapses in technique before they’re able to compromise a real preparation, enabling a documented finding rather than an adverse patient outcome.

“Media fill testing transforms routine aseptic practice into measurable evidence of process control, helping hospital pharmacies identify risks before they affect product quality or patient care.”

— Leonor Araújo, Product Manager, Traded Products, Life Sciences, AnalytiChem Group

How can hospital pharmacies build worst-case conditions into a media fill?

A media fill test performed under calm, unhurried conditions indicates very little to a hospital pharmacy about how its process holds up under the pressure it faces day to day; this is why worst-case simulation, not routine simulation, is where the real assurance value lies.

Simulating genuine worst-case conditions means deliberately including complex aseptic manipulations, multiple transfers and connections, extended processing durations and peak workload conditions, and both routine and non-routine interventions.

A recent scoping review — Best Practices to Reduce Microbial Contamination During Media-Fill Testing Process in Hospital Pharmacies, by Damiani, G. et al — set out several measures that consistently improve the reliability of hospital media fill programs. The review identifies five supporting practices that determine whether a media fill program produces reliable evidence over time, rather than a single reassuring data point.

• Comprehensive operator training. Personnel qualification is one of the strongest predictors of aseptic performance, and this should extend to every member of staff involved in sterile compounding, including pharmacists performing final product verification, not just the technicians creating the compound.
• Realistic simulation design. Media fill tests should mirror routine production as closely as possible, including the interruptions and critical interventions described above.
• Robust environmental monitoring. A monitoring program that tracks both viable and non-viable contamination in critical processing areas enables a hospital pharmacy to act on drift before it shows up in a media fill failure.
• Standardized procedures. Clearly documented, consistently applied procedures reduce the variability between operators that a media fill is otherwise likely to expose.
• Trending and continuous improvement. Media fill results should be tracked over time to identify recurring risks and support root-cause investigation, rather than treated as a series of unconnected pass or fail events.

These practices align closely with Annex 1’s direction away from a single periodic test, toward a continuously maintained, evidence-based CCS.

How should a failed media fill be investigated?

Any indication of microbial growth in a media fill unit should trigger a defined investigation rather than being treated as an isolated, dismissible event: the acceptance criteria for a media fill are deliberately strict given that the associated preparations are administered directly to vulnerable patients. A proper response includes an immediate investigation, root-cause analysis, assessment of the potential impact on any product or patient that may be affected by the underlying process, corrective and preventive action, and requalification of the operator or process where required.

It’s worth being precise about what a contaminated media fill does and doesn’t tell a hospital pharmacy.

It doesn’t automatically mean that a specific batch of real preparations was compromised, as the media fill and the batches produced around it are separate events, even if they share a process and an operator. What it does mean is that the aseptic process has demonstrated a weakness that must be understood and corrected before that process can be relied on again. Treating the two as equivalent understates the seriousness of a failure; treating them as unrelated understates what the failure is actually telling the unit about its risk level.

Does a passed media fill guarantee that every preparation is sterile?

A successful media fill demonstrates that a process performed acceptably during the specific period it was tested, but it does not, on its own, guarantee that every preparation compounded before or after that test was free of contamination. Media fill testing provides a snapshot of process capability, not a continuous certificate of sterility, and treating it as the latter is one of the more consequential misreadings a hospital pharmacy can make of its own quality data.

Sterility assurance in a hospital aseptic unit is the product of several systems working together, of which media fill testing is only one, alongside environmental monitoring, equipment qualification, cleaning and disinfection programs, ongoing personnel training, a functioning quality management system, and the wider contamination control strategy that ties them together. This is the same principle that runs through EU GMP Annex 1, United States Pharmacopeia (USP) guidance, and the European Pharmacopoeia alike: sterility is achieved through the sustained control of a process, not proven after the fact by testing its output. For everyone working in a hospital aseptic unit, that’s the distinction that matters most, because it’s the difference between treating a passed media fill as permission to relax, and treating it as one data point in an ongoing responsibility to patients.

Building sterility assurance into everyday practice

Media fill testing remains one of the most effective ways for a hospital aseptic unit to demonstrate that its compounding process, and the people implementing it, can maintain sterility under realistic operating conditions.

Under the revised EU GMP Annex 1, expectations around simulation design, personnel qualification, contamination control, and media quality are more explicit than ever. Hospital pharmacies should treat these expectations as a floor rather than a ceiling: simulations should reflect genuine worst-case scenarios, and the media used should be growth promotion-tested before any compounding session. Doing so serves to both strengthen compliance, and increase confidence in the patient safety that sits behind it.

Patients receiving these treatments aren’t thinking about aseptic technique. They’re focused on their health, the possible outcomes ahead of them, and whether the treatment they’re being given is going to work. A well-designed media fill program built around worst-case conditions, coupled with rigorous investigation of any failure, and an honest understanding of what a pass does and doesn’t prove, is how a hospital aseptic unit maintains that trust, and delivers the best for the patient. If you’re building or refreshing your media fill program, contact our team, or explore AnalytiChem’s range of Redipor ready-to-use biological media products, available off the shelf or tailored to your specific requirements.

References

1. EU GMP Annex 1: Manufacture of Sterile Medicinal Products (2022).
2. European Pharmacopoeia Chapter 2.6.1, Sterility.
3. USP General Chapter <797>, Pharmaceutical Compounding – Sterile Preparations.
4. Damiani, G. et al. (2025). Best Practices to Reduce Microbial Contamination During Media-Fill Testing Process in Hospital Pharmacies: A Scoping Review of Literature.